{
  "data": {
    "id": "stat_01M2KJ7XCG3Y4BJ2059JBJMGCT",
    "url": "https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT",
    "indicator": {
      "slug": "clinical-trial-country-use-share",
      "name": "Clinical trial country use share",
      "definition": "Percentage of total clinical trial country uses accounted for by a given region."
    },
    "industry": [
      {
        "slug": "pharmaceuticals",
        "name": "Manufacture of basic pharmaceutical products and pharmaceutical preparations",
        "isic": "C21",
        "is_primary": true
      }
    ],
    "region": {
      "code": "US",
      "name": "United States",
      "type": "country"
    },
    "period": {
      "start": "2021-01-01",
      "end": "2023-12-31",
      "type": "year"
    },
    "value": 16,
    "value_text": "16%",
    "unit": "percent",
    "currency": null,
    "scale": "1",
    "value_type": "actual",
    "source": {
      "org": "IQVIA Institute",
      "org_short_name": "IQVIA",
      "org_url": "https://www.iqvia.com",
      "org_tier": 3,
      "document_title": "Rethinking Clinical Trial Country Prioritization",
      "document_url": "https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization",
      "document_type": "press_release",
      "locator": "Country utilization is heavily consolidated in U.S., China and Western European countries",
      "quote": "The top 10 most used countries account for 58% of the total average pipeline country use, with the United States and China responsible for 16% and 13%, respectively, of total country-uses for trials started in the 2021–2023 timeframe.",
      "published_date": null,
      "accessed_at": "2026-09-15",
      "license": "see-source",
      "url_status": "ok"
    },
    "verification": "verified",
    "verified_by": "seed:auto-extract-v1",
    "verified_at": "2026-09-15T22:15:46.809Z",
    "confidence": 0.9,
    "is_secondhand": false,
    "supersedes": null,
    "superseded_by": null,
    "is_current": true,
    "citation": {
      "apa": "IQVIA Institute. (2023). Rethinking Clinical Trial Country Prioritization. Retrieved September 15, 2026, from https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT",
      "bibtex": "@misc{iqvia2023clinicalbjmgct,\n  author       = {{IQVIA Institute}},\n  title        = {Rethinking Clinical Trial Country Prioritization},\n  year         = {2023},\n  howpublished = {StatOrigin, https://statorigin.org},\n  url          = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGCT},\n  note         = {Original source: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/rethinking-clinical-trial-country-prioritization. Accessed September 15, 2026.}\n}"
    },
    "updated_at": "2026-09-15T22:15:46.809Z",
    "contested_by": [],
    "related": []
  },
  "meta": {
    "attribution": "Data from StatOrigin (https://statorigin.org), CC BY 4.0. Attribution required.",
    "license": "https://creativecommons.org/licenses/by/4.0/",
    "docs": "https://statorigin.org/docs/api",
    "total": 1
  }
}